Diabetes Drugs - A Major Breakthrough in Diabetes Control: Infinium Global Research

PUNE, India, March 2, 2020 /PRNewswire/ --  Millions of people worldwide are affected by diabetes, one of the most perturbing chronic diseases for its major economic and social impact.  Studies show that every 19 seconds, someone is diagnosed with this lifestyle disease. Additionally, factors such as aging of the population, changes in physical activity levels, and shift in the patterns of dietary intake factors are driving the rate of diabetes prevalence worldwide. Antidiabetic drugs play an important role in the lives of the diabetic population as the body loses its ability to use up blood sugar. And so, people with diabetes take antidiabetic drugs to control their blood glucose levels and avoid hypoglycemia and hyperglycemia for their entire lives. As the diabetes occurrence is growing at an alarming rate, the sales of the drugs will also continuously escalate over the coming years.  Infinium Global Research's recent report on the "Diabetes Drug Market (Drug Type - Injectable Drugs, and Oral Drugs; Application - Type 1 Diabetes, and Type 2 Diabetes): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025" provides a comprehensive outline of the factors responsible for the growth of the market.

Increasing Diagnosis of Type 2 Diabetes to Escalate the Demand for Novel Antidiabetic Drugs

At the current pace, 1 in 3 US adults is likely to have diabetes in their lifetime. The most common form of diabetes among the general population is type 2 diabetes. Type 2 diabetes accounts for about 95% of diabetes cases worldwide and types 1 diabetes accounts for the rest of diabetes cases worldwide. Diet, exercise, medication, and insulin therapy are the most common treatment for diabetes control. A large portion of the diabetic population affected with mild-to-moderate type 2 diabetes manage the condition with oral medications. Currently, 14 classes of drugs are available commercially to treat type 2 diabetes mellitus. A wide variety of non-insulin medications such as Metformin, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Alpha-glucosidase inhibitors (AGIs), Thiazolidinediones (TZDs) and many more are available for people with type 2 diabetes, and novel drugs emerge each year. Lantus and Januvia, are two of the highest-selling drugs of all time and represent some of the greatest breakthroughs in diabetes control.

Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/15261 

Onset of Type-1 Diabetes to Significantly Benefit the Top Players in the Diabetes Drugs Market

The type 1 diabetes is still the most common in children and insulin injections are a must for individuals with type 1 diabetes. Additionally, with the emergence of insulin pen and similar advanced devices for diabetic control, several patients are also preferring injections due to dosing accuracy, ease of use, ease of learning, and functionality. However, the skyrocketing prices of the insulin are worrying the growing patient pool with type 1 diabetes. The report on the "Global Diabetes Drugs Market" offers an in-depth analysis of the segments such as drug types (injectable drugs, and oral drugs) and applications (type 1 diabetes, and type 2 diabetes).

New and Improved Drugs to Flood the Diabetes Drug Market

In 2017 alone, USD 46 Billion was made from selling diabetes drugs worldwide. Moreover, it is estimated that 425 million people are living with diabetes all over the world and the incidence of diabetes mellitus is liable to increase and is almost certainly not going to decline, in the coming years. As the diabetes incidence continues to grow, the demand for diabetes drugs will also constantly intensify over the coming years. Additionally, the drug makers are also improving their product offerings with the development of new drugs which not only help patients control elevated blood sugar but also prevent cardiovascular complications of the disease over the long term. Ever since 2006, three new classes and more than a dozen new drugs have been launched for the treatment of diabetes.

Organic Growth Strategies to be the Fundamental Policy of the Key Players in the Diabetic Drug Market

Big pharma companies are engaged in product approvals for their launch in the marketplace. In September 2019, the Food and Drug Administration approved Danish drugmaker Novo Nordisk's Rybelsus, a new medication for Type 2 diabetes. Recently, in February 2020, the Food and Drug Administration extended the approval of Eli Lilly's Trulicity, the first-ever drug launched for the treatment of type 2 diabetes in 2014, for both preventing and reducing the risk of major adverse cardiovascular events in patients with type 2 diabetes. Furthermore, big pharma companies such as Celgene, GlaxoSmithKline, Allergan, and Novartis are expected to have big rollouts in the upcoming years in the diabetic drug segment. Infinium Global Research's recent report on the global Diabetes Drugs Market is an encompassment of such recent developments in the global marketplace. The report delivers insights into the leading players that have contributed greatly to the growth of the diabetes drug market and also estimates the impact of product innovations, similar to that of the aforementioned drugs on the global market. 

Asia Pacific Region to Generate the Largest Revenue in the Diabetes Drug Market

Geographically, diabetes drug revenue was the largest in the Asia Pacific region. The large population size, increased prevalence of diabetes, growing affordability of the population in the major Asian countries such as China and India are contributing significantly towards the rise of diabetic drug sales. In China alone, more than 100 million people have diabetes, according to the International Diabetes Federation. This number is more than any other country in the world. In addition, key pharmaceutical players such as Novo Nordisk, Sanofi, Merck & Co. Inc. have all made huge investments in the country by setting up sales, marketing and production facilities to benefit from the countries diabetes boom. North America's diabetic drug sales stands closer to Asia Pacific sales. In the U.S., the number of diabetic populations is closer to 30 million. In addition, the high prevalence of Type 1 diabetes and the high affordability of expensive insulin injectable aids the growth of diabetes drug sales in the U.S.

Need Assistance? Send an Enquiry@ https://www.infiniumglobalresearch.com/reports/enquiry/15261

Global Diabetes Drug Industry Coverage

Chapter - 1     Preface

• Report Description
• Research Methods
• Research Approaches

Chapter - 2     Executive Summary

• Diabetes Drug Market Highlights
• Diabetes Drug Market Projection
• Diabetes Drug Market Regional Highlights

Chapter - 3     Global Diabetes Drug Market Overview

• Introduction
• Market Dynamics
• Porter's Five Forces Analysis
• IGR-Growth Matrix Analysis
• Value Chain Analysis of Diabetes Drug Market

Chapter - 4     Diabetes Drug Market Macro Indicator Analysis

Chapter - 5     Global Diabetes Drug Market by Drug Type

• Injectable Drugs
• Oral Drugs

Chapter - 6     Global Diabetes Drug Market by Application

• Type 1 Diabetes
• Type 2 Diabetes

Chapter - 7     Global Diabetes Drug Market by Region 2019-2025

• North America
• Europe
• Asia-Pacific
• RoW

Chapter - 8     Company Profiles and Competitive Landscape

• Bayer healthcare
• Bristol-Myers Squibb
• Eli Lilly and Company
• Biocon ltd
• Piramal healthcare ltd
• Novartis AG
• GlaxoSmithKline
• Dr. Reddy's laboratories ltd
• Ranbaxy laboratories ltd
• Novo Nordisk
• Other Companies

Browse in-depth TOC on "Diabetes Drug Market"

About Us

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide the knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations and environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

Contact:

Mr. Shrikant Athavale
Infinium Global Research
Office No. 103 and 104,
Suratwala Mark Plazzo,
Hinjawadi, Pune,
Maharashtra, 
Pin- 411057.
USA: 1-888-500-3114
Email: [email protected] 
Research Insight: https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-diabetes-drug-market 
Visit Our Web Site: https://www.infiniumglobalresearch.com

SOURCE Infinium Global Research